Here are the 424B prospectus supplements from ALPS Group Inc (ALPS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ALPS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALPS filings page.
Alps Group Inc is registering up to 6,035,000 ordinary shares issuable upon exercise of outstanding warrants and up to 5,725,546 ordinary shares for resale by existing shareholders. The resale shares represent about 3.44% of the 166,400,326 ordinary shares outstanding as of this prospectus and include founder, PIPE, director and Business Combination consideration shares, some acquired at prices far below the current market price.
The company operates an integrated biotech, medical and wellness platform based in Malaysia. Its pipeline is entirely preclinical, so current revenue comes from aesthetic, healthcare and wellness services used to fund research in areas such as precision and preventive medicine. Warrants are exercisable at $11.50 per share, while the ordinary shares recently closed at $1.00, making exercises unlikely at present.
Key risks include the need for substantial additional funding, a material weakness in internal control over financial reporting, early‑stage clinical and regulatory uncertainty, dependence on third‑party manufacturing, potential selling pressure from registered resale shares, and the challenges of operating as an emerging growth, foreign private issuer based largely in Malaysia.